CST, 91585T, IGSF8 (F6M8L) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying IGSF8. Validated for Western Blotting. Available in 2 sizes. Highly specific and rigorously validated in-house, IGSF8 (F6M8L) Rabbit Monoclonal Antibody (CST #91585) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity IGSF8 (F6M8L) Rabbit mAb recognizes endogenous levels of total IGSF8 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val30 of human IGSF8 protein. Background Immunoglobulin superfamily member 8 (IGSF8), also known as CD316 or EWI-2, is a type-I transmembrane protein that belongs to the immunoglobulin superfamily (1-3). IGSF8 was initially characterized as a binding partner with CD9 and CD81, regulating vesicle trafficking (1). Recent work has focused on the role of IGSF8 in various cellular functions, such as cell motility, cell adhesion, innate immunity, neural development, and tumor biology (1-4). IGSF8 can act as a checkpoint for innate immunity by inhibiting natural killer (NK) cell response in cancer immunotherapy (3,7). Curiously, IGSF8 can exhibit contrasting roles in tumors, acting either as a tumor suppressor or an oncoprotein. In certain solid tumor cancers, such as lung, skin, prostate, and brain, IGSF8 suppresses tumor progression by inhibiting proliferation and metastasis (2,6-7). In contrast, in hematological malignancies like leukemias, IGSF8 sustains cancer cell stemness, which promotes therapy resistance and disease progression (6,8,9). IGSF8 has recently emerged as an innate immune checkpoint molecule in the tumor microenvironment (TME) (6). By inhibiting NK cell-mediated interactions with immune inhibitory receptors, IGSF8 reduces cytotoxicity, contributing to immune evasion in immunologically "cold" tumors, making the protein an interesting therapeutic target (6-8). test Alternate Names CD316; CD81 partner 3; CD81P3; EWI-2; EWI2; Glu-Trp-Ile EWI motif-containing protein 2; IGSF8; Immunoglobulin superfamily member 8; immunoglobulin superfamily, member 8; KCT-4; KCT4; Keratinocytes-associated transmembrane protein 4; LIR-D1; PGRL; Prostaglandin regulatory-like protein Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 70 Source/Isotype: Rabbit IgG